Doxorubicin Market Research Report – Global Forecast till 2027

Doxorubicin Market: Information by Application (liver cancer, lung cancer), By Distribution Channel (hospital pharmacy, retail pharmacy) - Forecast Till 2027

ID: MRFR/MED/5907-HCR | August 2022 | Region: Global | 85 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Doxorubicin Market, by Application

6.1 Introduction

6.2 Liver cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Gastric cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Breast cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Bone sarcoma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6 Prostate cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7 Stomach Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.8 Ovarian cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.9 Leukemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.10 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global DoxorubicinMarket, by Distribution Channel

7.1 Introduction

7.2 Hospital pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Retail pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Doxorubicin Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 Latin America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9. Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 Pfizer, Inc.

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Sun Pharmaceutical Industries Ltd..

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Janssen Pharmaceuticals

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Accord Healthcare.

10.4.1 Company Overview

10.4.2 Technologys/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Novartis AG.

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Sandoz.

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Dr. Reddy’s Laboratories Ltd.

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis


10.8 Teva Pharmaceuticals

10.8.1 Overview

10.8.2 Treatment Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.9 GLENMARK PHARMACEUTICALS LTD.

10.9.1 Overview

10.9.2 Treatment Overview

10.9.3 Financials

10.9.4 Key Developments

10.9.5 SWOT Analysis

10.10 Others.

10.10.1 Overview

10.10.2 Treatment Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

Chapter 11. Appendix

LIST OF TABLES

Table 1 Global Doxorubicin Market Synopsis, 2020-2027

Table 2 Global Doxorubicin Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Doxorubicin Market, by Region, 2020-2027 (USD Million)

Table 4 North America: DoxorubicinMarket, by Application, 2020-2027 (USD

Million)

Table 5 North America: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD

Million)

Table 6 US: Doxorubicin Market, by Application , 2020-2027 (USD Million)

Table 7 US: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD Million)

Table 8 Canada: Doxorubicin Market, by Application, 2020-2027 (USD

Million)

Table 9 Canada: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD

Million)

Table 10 South America: Doxorubicin Market, by Application, 2020-2027 (USD

Million)

Table 11 South America: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD

Million)

Table 12 Europe: Doxorubicin Market, by Application, 2020-2027 (USD Million)

Table 13 Europe: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD Million)

Table 14 Western Europe: Doxorubicin Market, by Application, 2020-2027

(USD Million)

Table 15 Western Europe: Doxorubicin Market, by Distribution Channel, 2020-2027

(USD Million)

Table 16 Eastern Europe: Doxorubicin Market, by Application, 2020-2027

(USD Million)

Table 17 Eastern Europe: Doxorubicin Market, by Distribution Channel, 2020-2027

(USD Million)

Table 18 Asia-Pacific: Doxorubicin Market, by Application, 2020-2027 (USD

Million)

Table 19 Asia-Pacific: Doxorubicin Market, by Distribution Channel, 2020-2027 (USD

Million)

Table 20 Middle East & Africa: Doxorubicin Market, by Application, 2020-2027

(USD Million)

Table 21 Middle East & Africa: Doxorubicin Market, by Distribution Channel, 2020-2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Doxorubicin Market

Figure 3 Segmentation Market Dynamics for Global Doxorubicin Market

Figure 4 Global Doxorubicin Market Share, by Application, 2020

Figure 5 Global Doxorubicin Market Share, by Distribution Channel, 2020

Figure 6 Global Doxorubicin Market Share, by Region, 2020

Figure 7 North America: Doxorubicin Market Share, by Country, 2020

Figure 8 Europe: Doxorubicin Market Share, by Country, 2020

Figure 9 Asia-Pacific: Doxorubicin Market Share, by Country, 2020

Figure 10 Middle East & Africa: Doxorubicin Market Share, by Country, 2020

Figure 11 Global Doxorubicin Market: Company Share Analysis, 2020 (%)

Figure 12 Pfizer, Inc: Key Financials

Figure 13 Pfizer, Inc: Segmental Revenue

Figure 14 Pfizer, Inc: Geographical Revenue

Figure 15 Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 16 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 17 Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 18 Janssen Pharmaceuticals: Key Financials

Figure 19 Janssen Pharmaceuticals: Segmental Revenue

Figure 20 Janssen Pharmaceuticals: Geographical Revenue

Figure 21 Accord Healthcare.: Key Financials

Figure 22 Accord Healthcare.: Segmental Revenue

Figure 23 Accord Healthcare.: Geographical Revenue

Figure 24 Novartis AG

Figure 25 Sandoz

Figure 26 Dr. Reddy’s Laboratories Ltd.

Figure 27 Teva Pharmaceuticals

Figure 28 GLENMARK PHARMACEUTICALS LTD

Doxorubicin Market Scenario

Doxorubicin market valued for USD 916.5 million and expected to register steady growth rate of 6.5% during the forecast period.

Segmentation

By Application Liver Cancer Lung Cancer
By Distribution Channel Hospital Pharmacy Retail Pharmacy

Key Players

  • Pfizer Inc
  • Sun Pharmaceutical Industries Ltd.
  • Janssen Pharmaceuticals
  • Accord Healthcare
  • Novartis AG
  • Sandoz
  • Reddy’s Laboratories Ltd.
  • Teva Pharmaceuticals
  • GLENMARK PHARMACEUTICALS LTD.

Drivers

  • Geriatric population and the growing prevalence of cancer
  • Increasing awareness programs for cancer treatment
Speak to Analyst Request a Free Sample

Doxorubicin Market Overview


The doxorubicin market accounts for USD 916.5 million in 2017 and expected to register steady growth rate of 6.5% during the forecast period. Doxorubicin is the generic drug used to treat cancer chemotherapy drugs Adriamycin and Rubex. It is an anthracycline antibiotic and belongs to the anti-cancer group of anti-cancer. The medications are antineoplastic and are made from the natural product produced by the bacterium Streptomyces peucetius var. caesius. Doctors use this for the treatment of different types of cancer. The cancers that can be treated through this are breast, stomach, ovary, bone, testicles, bladder, lung, soft tissue, osteogenic sarcoma, Wilms' tumour, Hodgkin's, and non-Hodgkin's lymphomas. Less commonly, it is also used to treat squamous cell carcinomas of the head and neck. Vagina and cervix, multiple refractory myeloma, and neuroblastoma. Doxorubicin slows down the proliferation rate of cancerous cells by intercalating between the base pairs in the DNA helix. And this can prevent DNA replication and inhibit protein synthesis. The market is facing good growth due to several reasons. One of the major reasons is the rise in cancer patients worldwide, which is the main cause of death. The lifestyle that people are adopting, which causes more cancer cells in the body, is another cause of the growth.


Segmentation


The doxorubicin market has been segmented on the basis of application, and distribution channel.


The application segment is divided into liver cancer, gastric cancer, breast cancer, bone sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.


The market, by distribution channel, has been segmented into hospital pharmacy, retail pharmacy and others.


The doxorubicin market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The doxorubicin market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Doxorubicin Market Share, by Region, 2017 (%)


Doxorubicin Market


Source: MRFR Analysis


The Americas are expected to dominate the doxorubicin market owing to the growing pool of cancer patients associated with increasing elderly population, strong presence of major manufacturers in the region, and adoption of advanced healthcare facilities coupled with increased awareness about cancer treatment in general population. In 2016, according to the National Cancer Institute in United states approximately USD 147.3 billion were spend for cancer care and around 15.5 million new cases of cancer were registered.


The European market is expected to be the second-largest doxorubicin market. The market growth in this region can be attributed to the growing prevalence of cancer along with rising healthcare expenditure is expected to drive the growth of the market. In 2016, according to European commission, the European nations invested 16.2% of its total expenditure on healthcare.


Asia-Pacific is expected to be the fastest-growing doxorubicin market during the forecast period owing to the continuously increasing investment in healthcare, increasing geriatric population in the region, and increasing opportunities for various manufacturers. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), 12.4% of the total Asian population is 60 or above 60-year-old and by 2050 one third of the population will cross 60 year.


The market in the Middle East & Africa is expected to account for the smallest share of the doxorubicin market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Market of Doxorubicin, by Application



  • Liver cancer

  • Gastric cancer

  • Breast cancer

  • Bone sarcoma

  • Prostate cancer

  • Stomach Cancer

  • Ovarian cancer

  • Leukemia

  • others


Market of Doxorubicin, by Distribution Channel



  • Hospital pharmacy

  • Retail pharmacy

  • Others


Market of Doxorubicin, by Region



  • Americas


    • North America


      • US

      • Canada


    • South America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Company Profiles    



  • Pfizer, Inc

  • Sun Pharmaceutical Industries Ltd.

  • Janssen Pharmaceuticals

  • Accord Healthcare

  • Novartis AG

  • Sandoz

  • Reddy’s Laboratories Ltd.

  • Teva Pharmaceuticals

  • GLENMARK PHARMACEUTICALS LTD.


Recent Development


April 2022


The research group of the University of Manitoba in Canada found that vitamin C improved markers of heart health and survival in rats given doxorubicin, mainly by reducing oxidative stress and inflammation. The new study assessed whether vitamin C could similarly help prevent doxorubicin's adverse effects on skeletal muscle.


The research found that DDX3X expression was significantly decreased in H9c2 cardiomyocytes treated with Dox. Ddx3x knockdown and RK-33 (DDX3X ATPase activity inhibitor) pretreatment exacerbated cardiomyocyte apoptosis and mitochondrial dysfunction induced by Dox treatment.


 May 2022


A team of researchers from the National University of Singapore (NUS) is best for novel magnetic therapy. This is delivered using the OncoFTX System, which serves as an effective companion therapy to chemotherapy to enhance treatment outcomes for breast cancer.

Intended Audience



  • Doxorubicin manufacturing suppliers and companies

  • Healthcare providers

  • Research institutes and academic centers

  • Contract manufacturing organizations (CMOs)

  • Market research and consulting



Report Scope:
Report Attribute/Metric Details
  Market Size   2017 : USD 916.5 million
  CAGR   6.5% (2018 - 2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Application, Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Doxorubicin market are Pfizer, Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK PHARMACEUTICALS LTD. and various others
  Key Market Opportunities   Strategic alliances, mergers and acquisitions and new product developments
  Key Market Drivers

  • Geriatric population and the growing prevalence of cancer
  • Increasing awareness programs for cancer treatment


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The global doxorubicin market was valued at USD 916.5 million in 2017.

    The global doxorubicin market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2018 to 2023.

    The global doxorubicin market is primarily driven by the growing geriatric population and the growing prevalence of cancer.

    The leading regional market for doxorubicin is the Americas, followed by Europe.

    Leading players in the doxorubicin market include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare, Novartis AG, Reddy’s Laboratories Ltd., and Teva, among others.